“COVID-19 accounts for nearly 10 percent of all lung transplants in the U.S., reflecting a major shift in transplant trends.

COVID-related lung transplants are particularly challenging due to severe lung damage and complex surgeries, leading to longer and more resource-intensive recoveries.

Lung transplant candidates with COVID-19 face similar survival rates to other lung transplant patients, but their aftercare involves a dramatic adjustment to lifelong medications and new health risks.”

bovhyaluronidase azoximer improved exercise tolerance and reduced breathlessness in post-COVID-19 patients.

Faster lung recovery was noted in those with cardiovascular issues after 180 days.

“Arthritis drugs already available for prescription have the potential to halt lingering lung problems that can last months or years after COVID-19 infections, new research from the University of Virginia School of Medicine and Cedars-Sinai suggests.

By examining damaged human lungs and developing an innovative new lab model, the scientists identified faulty immune processes responsible for the ongoing lung issues that plague an increasing number of people after they've otherwise recovered from COVID-19. These lasting harms of COVID infection, known as ‘post-infection lung fibrosis,’ have no good treatments. The new research, however, suggests that existing drugs such as baricitinib and anakinra can disrupt the malfunctioning immune response and finally allow damaged lungs to heal.”